Drugs / VS-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06987968 | Aug → Sep 2025 | cirrhosis of liver, hepatic encephalopathy | Genfit | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05900050 | Jul 2023 → Oct 2025 | liver disorder | Genfit | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Genfit | Results GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD genfit.com ↗
GENFIT’s decision follows the occurrence of a peritonitis case reported as Serious Adverse Event (SAE) in the UNVEIL-IT® clinical trial evaluating VS-01 in patients with ACLF grades 1, 2 or 3a and ascites and subsequent review and feedback from the independent Data Monitoring Committee (iDMC). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-19 | Genfit | GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD genfit.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05900050 ↗ |
| Modality | Other / unclassified | “intraperitoneal, liposomal formulation VS-01” NCT05900050 ↗ |
| Route | Other | “receive VS-01 intraperitoneally” NCT05900050 ↗ |